 |
 |
The Parkinson's Action Network (PAN) recently held two conference calls to update the Parkinson's community about Amgen's halt of its phase II GDNF trials, the future of GDNF research related to PD, and recent meetings at the FDA focused on safety concerns and possible "compassionate use" of GDNF for trial participants. You can read a report on these calls on Parkinson Pipeline Project http://www.pdpipeline.org/PAN_GDNF_calls.htm or on the Grassroots Connection website http://www.grassrootsconnection.com/grcissue_GDNF_research.htm Linda ---------------------------------------------------------------------- To sign-off Parkinsn send a message to: mailto:[log in to unmask] In the body of the message put: signoff parkinsn